Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Eppendorf is launching the new VisioNize® Laboratory News
The journey and merging of sperm and egg cells is
This year, the Hamburg based life sciences company
Cipla Limited (BSE: 5
Since it’s an ingredient in so many foods, you h
In a world constantly in motion, Microbioz India r
Glaucoma is a type of eye disease results damage to the optic nerve and vision loss. The most common type is open-angle glaucoma with less common types including closed-angle glaucoma and normal-tension glaucoma. According to World Health Organization, Gluacoma is one of leading cause of blindness and about 3 million of people infected with glaucoma in United States.
Researcher from American Academy of Ophthalmology recently develops an alternate medication of insertion of silicon ring in eye which continues releasing drug for better treatment and more as replaced intake of daily eye drops. The concern research study recently appears in Opthalmology, Journal of American Academy of Opthalmology.
Under experimental testing of this drug scientist inset silicon ring with bimatoprost type of glaucoma drug in 64 glaucoma patients and also supplied artificial tears and as a control they followed eye drops used 0.5 percent timolol drops two time a day about group of 66 patients and as a result the regulatory benchmark for glaucoma drugs. Eye pressure in the bimatoprost group fell 3.2 to 6.4 mmHg over six months, in comparison to 4.2 to 6.4 mmHG for the timolol group. Overall, eye pressure decreased in the group wearing the bimatoprost ring by about 20 percent from the initial measurements over six months.
"In making effective treatments easier for patients, the hope is that we can reduce vision loss from glaucoma, and possibly other diseases," said study author James D. Brandt, M.D., director of the UC Davis Medical Center Glaucoma Service. "What is exciting is that this is just one of several sustained-release drug delivery methods designed to help patients who have trouble taking daily eye drops."
Note: the above story is for information purposes for more information go through original story source.
Story source: American Academy of Opthalmology.
Journal References:
Brandt, et al. Six-month IOP Reduction with a Topical Bimatoprost Ocular Insert: Results of a Phase 2 Randomized Controlled Study. Ophthalmology, May 2016 DOI: 10.1016/j.ophtha.2016.04.026
